

Carbon Reduction Plan Template

Supplier name: ...GSK.....

Publication date:17th March 2023.....

Commitment to achieving Net Zero

GSK is committed to achieving Net Zero emissions by **2045**.

Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline Year: 2020	
Additional Details relating to the Baseline Emissions calculations.	
Historic baseline year emissions from 2020 onwards have been restated in 2023 following the demerger of GSK's Consumer Healthcare business to form Haleon in July 2022. The restatement excludes historic emissions that were allocated to the consumer healthcare business unit.	
Baseline year emissions:	
EMISSIONS	TOTAL (tCO₂e)
Scope 1	710,529
Scope 2	168,854
Scope 3 (Included Sources)	9,949,039
Total Emissions	10,828,422

Current Emissions Reporting

Reporting Year: 2022	
EMISSIONS	TOTAL (tCO ₂ e)
Scope 1	626,418
Scope 2	88,368
Scope 3 (Included Sources)	8,624,434 (the latest data available for scope 3 is based on 2021 activity)
Total Emissions	9,339,220

Emissions reduction targets

Following the demerger of the consumer healthcare business in July 2022, GSK has submitted an updated near-term carbon reduction target to 2030 and a new net zero long-term target to 2045 to the Science Based Targets initiative for validation.

Near term target

GSK commits to reduce absolute scope 1 & 2 (market approach) by 80% and scope 3 GHG emissions from Purchased goods and services, Fuel & Energy Related Activities, Upstream transportation and distribution, Waste Generated in Operations, Business travel, Employee commuting, Use of sold products and End-of-life treatment of sold products by 80% by 2030 from a 2020 base year.


Long term target

GSK commits to reduce absolute scope 1 & 2 (market approach) by 90% and scope 3 GHG emissions from Purchased goods and services, Capital goods, Fuel & Energy Related Activities, Upstream transportation and distribution, Waste Generated in Operations, Business travel, Employee commuting, Use of sold products and End-of-life treatment of sold products and investments by 90% by 2045 from a 2020 base year.

Our value chain carbon footprint


We have mapped our carbon footprint across our value chain to ensure we have a clear understanding of where to focus our efforts, which informs our pathway to net zero.

This is the first time we have restated our footprint as a fully focused biopharma company, following the demerger of our Consumer Healthcare business.



Our pathway to net zero

The graph below shows our projected carbon reduction pathway to 2030 and 2045 across the different parts of our carbon footprint, along with our planned offsets.



Carbon Reduction Projects

Completed Carbon Reduction Initiatives

GSK have reduced emissions from scope 1&2 by 19% by end of 2022 compared to our baseline year of 2020, equivalent to a reduction of 165,000 tonnes CO₂e. This has been achieved by increasing the amount of renewable electricity we buy and generate on site from 46% to 73% of the total electricity we source and through our energy efficiency programme which has seen the amount of energy we use reduce by 11% at the end of 2022 compared to our baseline year of 2020.

GSK's carbon reduction initiatives addressing emissions across scopes 1, 2 and 3 are shown in the graphic below

Priority actions to reduce emissions

We are taking action to reduce emissions across our full value chain, prioritising the highest impact areas.

Beyond 2030 we expect we will be left with the harder to tackle emissions from across our supply chain, our own operations, logistics, and disposal. Addressing these residual emissions will in many cases be dependent on technologies, infrastructure and regulatory frameworks that will require broad public/private collaboration, and so our decarbonisation is interdependent and following a similar timeframe to the broader economic transition.


Full carbon footprint includes 1% scope 3 emissions from the disposal of our products by GSK patients.

Purchased goods and services Scope 3 emissions



- Sustainable Procurement Programme, driving targeted supplier engagement and setting sustainability standards
- Deep engagement with 30 most impactful suppliers
- Peer collaboration through Energize programme to expand access to renewable electricity across our shared supply chains
- Manufacture 2030 helping with engagement, measurement and the development of emission reduction glidepaths for suppliers
- Activate programme with peers to reduce the environmental impact in Active Pharmaceutical Ingredient value chains

GSK's operations Scopes 1 and 2 emissions



- Renewable electricity and heat**
 - Members of RE100
 - Onsite production through wind turbines and solar panels, together with buying green electricity
 - Developing green heat strategy
- Electric vehicles**
 - Members of EV100
 - Committed to transition our sales fleet to low-carbon vehicles by 2030
 - Target to install charging infrastructure at 100 sites
- Energy reductions**
 - Ongoing focus on energy efficiency programmes

Logistics Scope 3 emissions



- Maximising transition from air freight to sea freight
- Ensuring full container optimization
- Sector peer collaboration to identify common logistic routes and to pilot 'green corridors'

Patient use Scope 3 emissions



- Predominantly from the propellant used in metered dose inhalers (MDIs) for asthma and chronic obstructive pulmonary disease
- Investing in an R&D programme to reduce greenhouse gas emissions, with good progress towards reformulating an alternative gas that could reduce the climate impact by up to 90%, if the clinical trials are successful
- Beyond MDIs, product stewardship programme to embed eco-design principles for all new products

Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard¹ and uses the appropriate Government emission conversion factors for greenhouse gas company reporting².

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard³.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

Signed on behalf of the Supplier:

Claire Lund, VP Sustainability, GSK

Date: 17th March 2023

¹<https://ghgprotocol.org/corporate-standard>

²<https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

³<https://ghgprotocol.org/standards/scope-3-standard>